<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234078</url>
  </required_header>
  <id_info>
    <org_study_id>037E-04-002</org_study_id>
    <secondary_id>JapicCTI-050040</secondary_id>
    <nct_id>NCT00234078</nct_id>
  </id_info>
  <brief_title>Dose-response Study of OPC-12759 Ophthalmic Suspension</brief_title>
  <official_title>Dose-response Study of OPC-12759 Ophthalmic Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension
      in dry eye patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF)</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. The change from baseline (CFB) to LOCF at the end of instillation (LOCF endpoint) was used to analyze dose-response. A general linear model was used to examine if slope parameters were not equal to zero.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Primary Ocular Discomfort (POD) Score From Baseline to Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>POD indicates the ocular symptom most bothersome to the patient. POD selected by each patient from among the following ocular symptoms; Foreign body sensation, Dryness, Photophobia, Eye pain and Blurred vision. POD was scored from 0 through 4; a score of 0 indicated no symptoms and a score of 4 indicated very severe symptoms. 0 is better. The change from baseline (CFB) to LOCF at the end of instillation (LOCF endpoint) was used to analyze dose-response. A general linear model was used to examine if slope parameters were not equal to zero.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>0.5% OPC-12759</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5% OPC-12759 (rebamipide) ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% OPC-12759</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% OPC-12759 (rebamipide) ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% OPC-12759</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% OPC-12759 (rebamipide) ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo of OPC-12759 (rebamipide) ophthalmic suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% OPC-12759</intervention_name>
    <arm_group_label>0.5% OPC-12759</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% OPC-12759</intervention_name>
    <arm_group_label>1% OPC-12759</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% OPC-12759</intervention_name>
    <arm_group_label>2% OPC-12759</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatient.

          2. Subjective complaint of dry eye that has been present for minimum 20 months.

          3. Primary ocular discomfort severity is moderate to severe.

          4. Corneal - conjunctival damage is moderate to severe.

          5. Unanesthetized Schirmer's test score of 7mm/5minutes or less.

          6. Best corrected visual acuity of 0.2 or better in both eyes.

        Exclusion Criteria:

          1. Presence of anterior segment disease or disorder other than that associated with
             keratoconjunctivitis sicca.

          2. Anticipated use of any topically-instilled ocular medications or patients with cannot
             discontinue the use during the study.

          3. Anticipated use of contact lens during the study.

          4. Any history of ocular surgery within 12 months.

          5. Female patients who are pregnant, possibly pregnant or breast feeding;

          6. Known hypersensitivity to any component of the study drug or procedural medications.

          7. Receipt of any investigational product within 4 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satoshi Oshima</last_name>
    <role>Study Director</role>
    <affiliation>Dermatologicals &amp; Ophthalmologicals Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Otsuka Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <results_first_submitted>January 20, 2014</results_first_submitted>
  <results_first_submitted_qc>January 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2014</results_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OPC-12759</keyword>
  <keyword>Dry eye syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.5% OPC-12759</title>
          <description>0.5% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>1% OPC-12759</title>
          <description>1% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>2% OPC-12759</title>
          <description>2% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>0% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.5% OPC-12759</title>
          <description>0.5% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>1% OPC-12759</title>
          <description>1% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>2% OPC-12759</title>
          <description>2% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>0% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="72"/>
            <count group_id="B5" value="290"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="13.6"/>
                    <measurement group_id="B2" value="62.5" spread="13.5"/>
                    <measurement group_id="B3" value="60.3" spread="11.5"/>
                    <measurement group_id="B4" value="56.0" spread="16.2"/>
                    <measurement group_id="B5" value="59.8" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF)</title>
        <description>FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. The change from baseline (CFB) to LOCF at the end of instillation (LOCF endpoint) was used to analyze dose-response. A general linear model was used to examine if slope parameters were not equal to zero.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.5% OPC-12759</title>
            <description>0.5% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1% OPC-12759</title>
            <description>1% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2% OPC-12759</title>
            <description>2% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>0% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF)</title>
          <description>FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. The change from baseline (CFB) to LOCF at the end of instillation (LOCF endpoint) was used to analyze dose-response. A general linear model was used to examine if slope parameters were not equal to zero.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="2.3"/>
                    <measurement group_id="O2" value="-3.1" spread="2.6"/>
                    <measurement group_id="O3" value="-2.1" spread="2.8"/>
                    <measurement group_id="O4" value="-2.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.385</p_value>
            <p_value_desc>versus placebo</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>a general linear model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Primary Ocular Discomfort (POD) Score From Baseline to Last Observation Carried Forward (LOCF)</title>
        <description>POD indicates the ocular symptom most bothersome to the patient. POD selected by each patient from among the following ocular symptoms; Foreign body sensation, Dryness, Photophobia, Eye pain and Blurred vision. POD was scored from 0 through 4; a score of 0 indicated no symptoms and a score of 4 indicated very severe symptoms. 0 is better. The change from baseline (CFB) to LOCF at the end of instillation (LOCF endpoint) was used to analyze dose-response. A general linear model was used to examine if slope parameters were not equal to zero.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.5% OPC-12759</title>
            <description>0.5% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1% OPC-12759</title>
            <description>1% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2% OPC-12759</title>
            <description>2% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>0% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Primary Ocular Discomfort (POD) Score From Baseline to Last Observation Carried Forward (LOCF)</title>
          <description>POD indicates the ocular symptom most bothersome to the patient. POD selected by each patient from among the following ocular symptoms; Foreign body sensation, Dryness, Photophobia, Eye pain and Blurred vision. POD was scored from 0 through 4; a score of 0 indicated no symptoms and a score of 4 indicated very severe symptoms. 0 is better. The change from baseline (CFB) to LOCF at the end of instillation (LOCF endpoint) was used to analyze dose-response. A general linear model was used to examine if slope parameters were not equal to zero.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.1"/>
                    <measurement group_id="O2" value="-1.4" spread="1.0"/>
                    <measurement group_id="O3" value="-1.3" spread="1.1"/>
                    <measurement group_id="O4" value="-1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.601</p_value>
            <p_value_desc>versus placebo</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>a general linear model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Week 12</title>
        <description>FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. The CFB in the FCS scores were compared between the 0.5, 1 and 2% rebamipide group and the placebo group using a Dunnett’s t-test</description>
        <time_frame>Baseline, 12week</time_frame>
        <population>From the FAS of 290 patients, 218 patients who had no punctal plug insertion or punctal occlusion and who had a baseline schirmer test value of equal to or less than 5 mm for the eye evaluated for efficacy were selected and subjected to exploratory data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>0.5% OPC-12759</title>
            <description>0.5% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1% OPC-12759</title>
            <description>1% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2% OPC-12759</title>
            <description>2% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>0% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Week 12</title>
          <description>FCS indicates the damage to the corneal epithelium. Per the National Eye Institute/Industry Workshop report, the cornea was divided into 5 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-15). 0 is better. The CFB in the FCS scores were compared between the 0.5, 1 and 2% rebamipide group and the placebo group using a Dunnett’s t-test</description>
          <population>From the FAS of 290 patients, 218 patients who had no punctal plug insertion or punctal occlusion and who had a baseline schirmer test value of equal to or less than 5 mm for the eye evaluated for efficacy were selected and subjected to exploratory data analysis</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="2.1"/>
                    <measurement group_id="O2" value="-3.5" spread="2.4"/>
                    <measurement group_id="O3" value="-2.9" spread="2.5"/>
                    <measurement group_id="O4" value="-2.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.421</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline to Week 12</title>
        <description>LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctiva was divided into 6 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-18). 0 is better. The CFB in the LGCS scores were compared between the 0.5, 1 and 2% rebamipide group and the placebo group using a Dunnett’s t-test.</description>
        <time_frame>Baseline, 12weeks</time_frame>
        <population>From the FAS of 290 patients, 218 patients who had no punctal plug insertion or punctal occlusion and who had a baseline schirmer test value of equal to or less than 5 mm for the eye evaluated for efficacy were selected and subjected to exploratory data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>0.5% OPC-12759</title>
            <description>0.5% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>1% OPC-12759</title>
            <description>1% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>2% OPC-12759</title>
            <description>2% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>0% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lissamine Green Conjunctival Staining (LGCS) Score From Baseline to Week 12</title>
          <description>LGCS indicates the damage to the conjunctival epithelium. Per the National Eye Institute/Industry Workshop report, the conjunctiva was divided into 6 fractions, each of which was given a staining score from 0 to 3, and the total score was calculated (0-18). 0 is better. The CFB in the LGCS scores were compared between the 0.5, 1 and 2% rebamipide group and the placebo group using a Dunnett’s t-test.</description>
          <population>From the FAS of 290 patients, 218 patients who had no punctal plug insertion or punctal occlusion and who had a baseline schirmer test value of equal to or less than 5 mm for the eye evaluated for efficacy were selected and subjected to exploratory data analysis</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.1"/>
                    <measurement group_id="O2" value="-4.5" spread="3.3"/>
                    <measurement group_id="O3" value="-4.2" spread="3.2"/>
                    <measurement group_id="O4" value="-2.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.5% OPC-12759</title>
          <description>0.5% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>1% OPC-12759</title>
          <description>1% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>2% OPC-12759</title>
          <description>2% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>0% rebamipide ophthalmic suspension received one drop of to both eyes four times a day for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.0</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="74"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="72"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="72"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="74"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Dysgeusia (bitter taste)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="72"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="72"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="74"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research and Development</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ltd.</organization>
      <phone>+81-3-6361-7366</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

